Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 359.27 USD 0% Market Closed
Market Cap: 47.5B USD

Net Margin

1.4%
Current
Improving
by 35.8%
vs 3-y average of -34.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
1.4%
=
Net Income
$43.6m
/
Revenue
$3.2B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
1.4%
=
Net Income
$43.6m
/
Revenue
$3.2B

Peer Comparison

Country Company Market Cap Net
Margin
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.2B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...
No Stocks Found

Market Distribution

In line with most companies in the United States of America
Percentile
45th
Based on 15 072 companies
45th percentile
1.4%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Alnylam Pharmaceuticals Inc
Glance View

In the heart of the biotechnology revolution, Alnylam Pharmaceuticals Inc. has been a pioneering force, transforming the landscape of medicine through its innovative use of RNA interference (RNAi) technology. Founded in 2002 and based in Cambridge, Massachusetts, the company set out on a bold mission to silence disease-causing genes by targeting RNA, the intermediary that carries genetic instructions necessary for protein synthesis. This groundbreaking approach diverges from traditional methods that focus on targeting proteins directly and instead intervenes earlier in the disease process to eliminate or reduce the proteins before they can wreak havoc on the body. Fueled by extensive research and a robust pipeline, Alnylam has successfully brought several RNAi-based therapies to market, such as Onpattro and Givlaari, which address rare genetic disorders with high unmet medical needs. Alnylam's business model is centered around the commercial success of its novel therapies, partnerships with other pharmaceutical giants, and strategic collaborations for global distribution. By securing alliances with industry leaders like Sanofi and Regeneron, Alnylam has been able to expand its research capabilities and broaden its market reach. Revenue for the company is primarily driven by the sales of its approved products, which continue to grow as they gain acceptance within the medical community. Additionally, Alnylam's extensive patent portfolio and its strategic licensing agreements provide an additional revenue stream, safeguarding its innovations and ensuring it retains a competitive edge in this rapidly advancing field. Through its relentless pursuit of innovation, Alnylam continues to position itself as a trailblazer in turning the once theoretical promise of RNAi into a clinical reality.

ALNY Intrinsic Value
385.67 USD
Undervaluation 7%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
1.4%
=
Net Income
$43.6m
/
Revenue
$3.2B
What is Alnylam Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Alnylam Pharmaceuticals Inc is 1.4%, which is above its 3-year median of -34.4%.

How has Net Margin changed over time?

Over the last 3 years, Alnylam Pharmaceuticals Inc’s Net Margin has increased from -123% to 1.4%. During this period, it reached a low of -123% on Sep 30, 2022 and a high of 1.4% on Sep 30, 2025.

Back to Top